fr   en
Fundraisings



Browse by date
Or search by keyword
Date: 2010-09-08
Company: Addex Pharmaceuticals (Switzerland)
Investors: The Michael J. Fox Foundation (USA)
Amount: $900,000
Planned use: This $900,000 grant from The Michael J. Fox Foundation will help fund a Phase II study of ADX48621 for the treatment of Parkinson's disease levodopa-induced dyskinesia.
The metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator already has successfully completed Phase I testing in three studies involving a total of 130 patients, including older healthy volunteers. The Phase II study of ADX48621 to treat PD-LID is expected to start in the U.S. and EU during the fourth quarter of 2010.
Other: